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As amedical humanitarian organisation diagnosing and treating
people with neglected diseases for almost 30 years,1 2Médecins
Sans Frontières (MSF) understands only too well that the dearth
of research and development for new tools to treat these
diseases3 is directly attributable to insufficient funding and
incentives.
Innovative incentive mechanisms for research and development,
including “pull” mechanisms, such as the US Food and Drug
Administration priority review voucher, are crucial to spurring
innovation in areas lacking conventional market pull of revenue
derived from high prices of products and high volumes of sales.
However, the priority review voucher awarded to Knight
Therapeutics for a product Knight neither developed nor
manufactures—and which is not easily procured at affordable
prices—highlights the shortfalls of the voucher as it is currently
designed. Its effectiveness is limited by its failure to ensure it
rewards genuine innovation, a lack of obligations to guarantee
affordability and patient access to treatments, administrative
restrictions that might limit its potential value to innovators,
and a limited list of explicitly eligible diseases.
MSF is urging US Congress to amend the legislation governing
the priority review voucher to correct these shortfalls. Changes
could include restricting awards to treatments not previously
developed or registered elsewhere, conditioning awards on the
implementation of access policies, adopting previously proposed
updates to rules of how the voucher is used, and making eligible
all neglected tropical diseases listed by the World Health
Organization, and other neglected conditions.4
Amendments to the legislation governing the priority review
voucher are necessary for it to fulfil its role in stimulating
meaningful investments in neglected disease research and
development. The voucher is not enough to deal with unmet
medical needs for neglected diseases, however. Congress must
also consider additional incentive mechanisms for research and
development that promote research collaboration, “de-link”
costs of research and development for treatments for neglected
diseases from the price of the end product, and ensure access
and affordability of treatments.5
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